Introduction

The biopharmaceuticals industry demands new production platforms to address several challenges; such as cost reduction to make biologics accessible in low-income countries, safety enhancement of the product, development of products administered by noninvasive routes, and expansion of potential biosimilars and biobetters. Microalgae are emerging hosts for biopharmaceuticals production with the potential to meet such requirements.

Areas covered

Nowadays successful cases on the production of vaccines, antibodies, antimicrobial peptides, growth factors/cytokines, and hormones in algae have been reported. This review comprises an updated outlook covering protein expression strategies, a compilation of functional biopharmaceuticals produced in algae, and companies investing in this technology.

Expert opinion

Key perspectives for the field include optimizing yields, scaling up production and completing preclinical trials. The experience from the field of plant-made biopharmaceuticals is commented as a key reference that will aid in the development of the algae-made biopharmaceuticals field.

中文翻译：

---

藻类生物制药领域的最新进展。

介绍

生物制药行业需要新的生产平台来应对若干挑战。例如降低成本以在低收入国家/地区使用生物制剂，提高产品安全性，开发通过非侵入性途径管理的产品以及扩大潜在的生物仿制药和生物仿制药。微藻类是新兴的生物制药生产宿主，有望满足此类要求。

覆盖区域

如今，已经报道了在藻类中生产疫苗，抗体，抗菌肽，生长因子/细胞因子和激素的成功案例。这篇综述涵盖了涵盖蛋白质表达策略的最新观点，藻类中生产的功能性生物药物的汇编以及对该技术进行投资的公司。

专家意见

该领域的主要观点包括优化产量，扩大生产规模和完成临床前试验。来自植物生物制药领域的经验被认为是关键参考，将有助于藻类生物制药领域的发展。